Pfizer Says Long-Awaited Lyme Vaccine Was Effective in Study

While the reported efficacy of 73% is promising, the limited number of cases raises questions about the vaccine's potential impact in real-world scenarios. Further studies will be crucial to validate these findings and to understand the vaccine's performance in diverse populations and environments. The challenges faced in this trial highlight the complexities of vaccine development, particularly for diseases with fluctuating incidence rates like Lyme disease.